BioTuesdays

Tag - ABOS

Markets

Cantor starts Acumen Pharma at OW; PT $13

Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with an “overweight” rating and 12-month price target of $13. The stock closed at $5.45 on May 17. Acumen is a neuro-Innovator leveraging its...

May 19, 2023
Acumen Pharmaceuticals Logo
Markets

HCW starts Acumen Pharma at buy; PT $15

H.C. Wainwright initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $15 price target. The stock closed at $4.88 on June 29. Acumen is a clinical-stage biopharmaceutical company developing...

June 30, 2022
Acumen
Markets

Stifel starts Acumen Pharma at buy; PT $27

Stifel launched coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with a “buy” rating and $27 price target. The stock closed at $17.08 on July 23. Acumen is a biotechnology company focused on the development of a next...

July 26, 2021